SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2003
|
CERUS CORPORATION |
||||
|
(Exact name of registrant as specified in its charter) |
||||
|
|
|
|
|
|
|
Delaware |
|
0-21937 |
|
68-0262011 |
|
(State of jurisdiction) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
2411
Stanwell Drive |
||||
|
(Address of principal executive offices and zip code) |
||||
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (925) 288-6000 |
||||
Item 5. Other Events.
On June 4, 2003, Cerus Corporation (the “Company”) and Baxter International, Inc. (“Baxter”) announced that the Company and Baxter reached agreement with the U.S. Food and Drug Administration on steps for regulatory approval for their pathogen inactivation system for platelets. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 7. Exhibits.
|
Exhibit |
|
Description of Exhibit |
|
99.1 |
|
Press Release, dated June 4, 2003, entitled “Baxter and Cerus Reach Agreement With FDA On Steps To Gain Regulatory Approval For Innovative Pathogen Inactivation System.” |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
CERUS CORPORATION |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: |
June 4, 2003 |
By: |
/s/ Gregory W. Schafer |
|
|
|
|
|
Gregory W. Schafer |
|
|
|
|
|
Vice President,
Finance and |
|
3
Index to Exhibits
|
Exhibit |
|
Description of Exhibit |
|
99.1 |
|
Press Release, dated June 4, 2003, entitled “Baxter and Cerus Reach Agreement With FDA On Steps To Gain Regulatory Approval For Innovative Pathogen Inactivation System.” |
4